Metformin May Improve Clinical Outcomes in Comorbid Heart Failure and Diabetes
Researchers assessed the clinical outcomes of patients with comorbid heart failure and diabetes receiving treatment with metformin and sulfonylurea.
Researchers assessed the clinical outcomes of patients with comorbid heart failure and diabetes receiving treatment with metformin and sulfonylurea.
Researchers analyzed the association between anemia and CV mortality, all-cause mortality, and major bleeding in patients with atrial fibrillation.
Researchers examined the relationship between a drop in systolic BP, worsening renal function, and prognosis in people with acute heart failure.
Researchers reported their findings on the effects of antihypertensive dosing in morning vs evening on patient prognosis at AHA 2021.
Researchers at AHA 2021 presented a study that sought to determine whether high leptin affects the risk for mortality or morbidity in patients with stable CHD.
Among patients with type 2 diabetes, empagliflozin showed greater benefits in patients with CVD vs without.
A network meta-analysis was done to compare the effectiveness of SGLT2 inhibitors in participants with type 2 diabetes and cardiovascular risk factors.
In a landmark trial presented at AHA 2021, researchers aimed to understand the safety and efficacy of direct oral anticoagulants vs vitamin K antagonists in Black patients with non-valvular atrial fibrillation and venous thromboembolism.
In a study presented at AHA 2021, researchers aimed to assess the link between cancer therapy-related cardiac dysfunction and immune checkpoint inhibitors.
A team of researchers analyzed the effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on patients with COVID-19 with preexisting hypertension.